Securities code: Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) securities abbreviation: Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) Announcement No.: 2022015 Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932)
2021 annual performance express
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Special note: the financial data of 2021 contained in this announcement is only preliminary accounting data, which has been audited by the company’s internal audit department and has not been audited by an accounting firm, and may be different from the final data disclosed in the 2021 annual report. The specific financial data shall be subject to the company’s 2021 annual report and audit report.
1、 Main financial data and indicators in 2021
Unit: Yuan
Increase and decrease of the project in the same period of last year in the reporting period
Total operating income 28298295463095909919630 195.05%
Operating profit 16978138357956227891814 201.95%
Total profit 16945566875955670131495 204.39%
Net profit attributable to shareholders of listed companies 14132244340346892779421 201.37%
Net profit attributable to shareholders of listed company after deducting non recurring profit and loss 14066399768845508226561 209.10%
Basic earnings per share (yuan / share) 14.79 4.99 196.39%
Weighted average return on net assets 78.89%, 55.81%, 23.08%
Increase and decrease at the end of the reporting period
Total assets 341708981018142664552377 139.52%
Owner’s equity attributable to shareholders of listed companies 278882463500110179329420 153.12%
Share capital 104877931006900514700 51.99%
Net assets per share attributable to shareholders of the listed company 26.59 15.97 66.50%
2、 Description of operating performance and financial status
(I) operating conditions, financial conditions and main factors affecting operating performance during the reporting period
1. Operation during the reporting period:
In 2021, the company achieved a total operating revenue of 28298295 million yuan, an increase of 195.05% over the previous year; The net profit attributable to the owners of the parent company was 1413224400 yuan, an increase of 201.37% over the previous year; The net profit attributable to the owner of the parent company after deducting non recurring profits and losses was 140664 million yuan, an increase of 209.10% over the previous year.
2. Financial status during the reporting period:
At the end of 2021, the total assets of the company were 34170898 million yuan, an increase of 139.52% over the beginning of the year; The owner’s equity attributable to the parent company was 2788824600 yuan, an increase of 153.12% over the beginning of the year.
3. Main factors affecting operating performance:
In 2021, the epidemic situation of covid-19 in many places in China was repeated, and the epidemic prevention and control policy of covid-19 nucleic acid detection was generally implemented in all places, which increased the demand for covid-19 nucleic acid detection reagent. With the company’s products with high sensitivity, convenient operation and high-quality customer service, the market share of covid-19 nucleic acid detection reagent continued to rise, and the related income of covid-19 nucleic acid detection reagent and service increased significantly.
In 2021, the covid-19 epidemic broke out in Delta and Omicron overseas, and the market demand for covid-19 antigen detection kit increased. The company’s covid-19 antigen detection kit obtained the certification of EU, Vietnam, Malaysia and other countries, and the relevant income increased significantly.
(II) the main reasons for the increase or decrease of relevant items in the above table is more than 30%
1. In 2021, the company’s operating revenue increased by 195.05%, operating profit increased by 201.95%, total profit increased by 204.39%, net profit attributable to the owner of the parent company increased by 201.37%, net profit attributable to the owner of the parent company after deducting non recurring profit and loss increased by 209.10% compared with the previous year, and basic earnings per share increased by 196.39% compared with the previous year in 2021, The main reason is: affected by the epidemic, the company’s revenue of covid-19 nucleic acid detection reagent and covid-19 antigen detection reagent increased significantly, resulting in the synchronous growth of corresponding profits.
2. At the end of 2021, the total assets of the company increased by 139.52% over the beginning of the year, the owner’s equity attributable to the parent company increased by 153.12% over the beginning of the year, and the net assets per share attributable to the owner of the parent company increased by 66.50% over the beginning of the year. The main reasons are that the operating income and net profit of the company increased significantly during the reporting period, resulting in the simultaneous growth of corresponding undistributed profits, which promoted the significant increase of the asset scale of the company. At the end of 2021, the total share capital of the company was 104877931 shares, an increase of 35872784 shares over the end of 2020, mainly due to the conversion of capital reserve into share capital and the listing of non-public issuance of new shares.
3、 Description of the difference from the previous performance estimate
There is no significant difference between the operating performance disclosed in this performance express and the disclosed performance forecast for 2021, and the net profit attributable to the shareholders of the listed company in 2021 is within the expected range. See the annual performance forecast of 2021 (Announcement No.: 2022001) disclosed by the company on January 5, 2022 for details of the performance forecast of 2021.
4、 Other instructions
This performance express is the preliminary calculation result of the company’s financial department and has not been audited by the audit institution. The company will disclose specific financial data in detail in the 2021 annual report. Please make careful decisions and pay attention to investment risks.
5、 Documents for future reference
1. The comparative balance sheet and income statement signed and sealed by the current legal representative, the person in charge of accounting and the person in charge of accounting of the company.
2. The internal audit report signed by the head of the internal audit department.
It is hereby announced.
Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932)
Board of directors
April 14, 2022
